Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 3.96B +24.6% |
| Revenue (ttm) | 682.20M +86.3% |
| Net Income | -702.23M |
| EPS | -16.00 |
| Shares Out | 49.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 732,091 |
| Open | 76.79 |
| Previous Close | 76.89 |
| Day's Range | 75.94 - 81.18 |
| 52-Week Range | 53.89 - 91.53 |
| Beta | 0.33 |
| Analysts | Strong Buy |
| Price Target | 103.44 (+28.85%) |
| Earnings Date | Nov 3, 2026 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ... [Read more]
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price target is $103.44, which is an increase of 28.85% from the latest price.
News
Tarsus Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Q3 growth was 64% YoY, driven by DTC, expanded field coverage, broader patient reach, and retreatment. Pipeline milestones include rosacea and Lyme data in H1 2027 and NORTHSTAR data in H2 2029.
Tarsus Pharmaceuticals price target raised to $102 from $94 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $102 from $94 and keeps an Outperform rating on the shares.
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
Tarsus Pharmaceuticals price target raised to $97 from $89 at Guggenheim
Guggenheim raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $97 from $89 and keeps a Buy rating on the shares.
Tarsus Pharmaceuticals price target raised to $103 from $100 at Oppenheimer
Oppenheimer raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $103 from $100 and keeps an Outperform rating on the shares. The firm notes the company’s Q3 beat and…
Tarsus Pharmaceuticals price target raised to $106 from $88 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $106 from $88 and keeps a Buy rating on the shares. The company reported an “impressive” record $194.6M…
Tarsus Pharmaceuticals reports Q3 EPS ($14.40), consensus ($3.04)
Reports Q3 revenue $194.57M, consensus $186.6M. “Ten years ago, we started Tarsus with the conviction that patients with overlooked diseases deserved better,” said Bobby Azamian, M.D., Ph.D., Chief Ex...
Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 XDEMVY sales rose nearly 64% YoY to $194.6 million, with record prescriptions and higher FY 2026 sales guidance. Cash of approximately $310 million supports pipeline investment, including several near-term clinical milestones.
Tarsus Pharmaceuticals Earnings release: Q3 2026
Tarsus Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Tarsus Pharmaceuticals Quarterly report: Q3 2026
Tarsus Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Tarsus Pharmaceuticals Slides: Q3 2026
Tarsus Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Tarsus Reports Third Quarter 2026 Financial Results
Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cum...
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2...
Tarsus Pharmaceuticals price target lowered to $94 from $100 at Mizuho
Mizuho lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $94 from $100 and keeps an Outperform rating on the shares.
Tarsus Pharmaceuticals appoints Neera Clase as chief commercial officer
Tarsus Pharmaceuticals (TARS) announced the appointment of Neera Clase as chief commercial officer, or CCO, effective Nov. 1. Clase has served as Tarsus’ interim chief commercial officer since July an...
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer
IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. ...
Tarsus Pharmaceuticals files to sell 2.91M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.91M shares of common stock. The company is not selling any…
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (...
Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Tarsus Pharmaceuticals (TARS) with a Buy rating and $116 price target Goldman resumed coverage of the biotechnology sector, saying the group ha...
Tarsus Pharmaceuticals reinstated with an Overweight at Barclays
Barclays reinstated coverage of Tarsus Pharmaceuticals (TARS) with an Overweight rating and $110 price target following the close of the Alkeus deal. The firm says its more bullish view on…
Tarsus Pharmaceuticals price target raised to $105 from $88 at Jefferies
Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $105 from $88 and keeps a Buy rating on the shares. The firm notes the stock has rallied post…
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approv...
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease
Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gilde...
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease
CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today annou...
Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $100 from $97 and keeps an Outperform rating on the shares. The firm is updating its…